- Home
- IMNN vs MDRR Comparison
IMNN vs MDRR Comparison
Compare IMNN & MDRR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- MDRR
- Stock Information
- Founded
- IMNN 1982
- MDRR 2015
- Country
- IMNN United States
- MDRR United States
- Employees
- IMNN N/A
- MDRR N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- MDRR Real Estate Investment Trusts
- Sector
- IMNN Health Care
- MDRR Real Estate
- Exchange
- IMNN Nasdaq
- MDRR Nasdaq
- Market Cap
- IMNN 12.9M
- MDRR 18.0M
- IPO Year
- IMNN 1985
- MDRR 2018
- Fundamental
- Price
- IMNN $5.06
- MDRR N/A
- Analyst Decision
- IMNN Buy
- MDRR
- Analyst Count
- IMNN 2
- MDRR 0
- Target Price
- IMNN $182.61
- MDRR N/A
- AVG Volume (30 Days)
- IMNN 164.0K
- MDRR 1.4K
- Earning Date
- IMNN 11-06-2025
- MDRR 11-11-2025
- Dividend Yield
- IMNN N/A
- MDRR 2.02%
- EPS Growth
- IMNN N/A
- MDRR N/A
- EPS
- IMNN N/A
- MDRR N/A
- Revenue
- IMNN N/A
- MDRR $9,649,145.00
- Revenue This Year
- IMNN N/A
- MDRR N/A
- Revenue Next Year
- IMNN N/A
- MDRR N/A
- P/E Ratio
- IMNN N/A
- MDRR N/A
- Revenue Growth
- IMNN N/A
- MDRR N/A
- 52 Week Low
- IMNN $4.60
- MDRR $9.55
- 52 Week High
- IMNN $41.22
- MDRR $15.00
- Technical
- Relative Strength Index (RSI)
- IMNN 43.66
- MDRR 52.34
- Support Level
- IMNN $4.60
- MDRR $13.13
- Resistance Level
- IMNN $5.15
- MDRR $13.99
- Average True Range (ATR)
- IMNN 0.28
- MDRR 0.10
- MACD
- IMNN -0.01
- MDRR -0.09
- Stochastic Oscillator
- IMNN 48.42
- MDRR 36.87
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
About MDRR Medalist Diversified REIT Inc.
Medalist Diversified REIT Inc is engaged to acquire, reposition, renovate, lease, and manage income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its reportable segments were retail center properties, flex center properties, and STNL properties.